Bilimsel çalışmalar

Prof. Dr. Ahmet Taner Sümbül

127 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Kaynak: OpenAlex

  2. Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

    Lung Cancer, 2026

    DOI 10.1016/j.lungcan.2026.109590 PMID 42664544 Açık erişimli tam metinKaynak: ORCID

  3. Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study

    JCO Oncology Practice, 2026

    DOI 10.1200/op-25-01248 PMID 42234938 Açık erişimli tam metinKaynak: OpenAlex

  4. Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20659 Kaynak: OpenAlex

  5. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

    Clinical Lung Cancer, 2025

    DOI 10.1016/j.cllc.2025.07.015 PMID 40813186 2 atıf (Europe PMC) Kaynak: OpenAlex

  6. The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20501 Açık erişimli tam metinKaynak: OpenAlex

  7. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

    Medicina, 2025

    DOI 10.3390/medicina61040638 PMID 40282929 5 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  8. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 atıf (Europe PMC) Kaynak: OpenAlex

  9. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  10. 46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102625 Açık erişimli tam metinKaynak: OpenAlex

  11. Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e20512 Açık erişimli tam metinKaynak: OpenAlex

  12. Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study

    Bursa Uludag University - AVESIS, 2024

    Kaynak: OpenAlex

  13. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

    Acta Oncologica, 2023

    DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  15. Pertuzumab-mediated Cardiotoxicity: A Single Center Study.

    Sakarya Medical Journal, 2023

    DOI 10.31832/smj.1163527 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  16. Thoracic Radiotherapy Effect on the Outcome in Extensive Stage Small Cell Lung Cancer

    Journal of College of Physicians And Surgeons Pakistan, 2023

    DOI 10.29271/jcpsp.2023.02.188 PMID 36797629 Açık erişimli tam metinKaynak: OpenAlex

  17. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma

    International Journal of Clinical Oncology, 2022

    DOI 10.1007/s10147-021-02072-x PMID 34762201 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  18. Sarkomlar ve Cilt Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1097 Açık erişimli tam metinKaynak: OpenAlex

  19. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Açık erişimli tam metinKaynak: OpenAlex

  20. By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with It

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-90068 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  21. Baş Boyun ve Santral Sinir Sistemleri Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1075 Açık erişimli tam metinKaynak: OpenAlex

  22. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

    International Journal of Clinical Oncology, 2021

    DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 atıf (Europe PMC) Kaynak: ORCID

  23. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.409 1 atıf (OpenAlex) Kaynak: OpenAlex

  24. Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

    Journal of International Medical Research, 2021

    DOI 10.1177/03000605211053755 PMID 34898302 14 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  25. Upfront thoracic radiotherapy to primary lesion improves outcomes in patients with stage IV non-small cell lung cancer harboring EGFR mutations.

    PubMed, 2021

    PMID 34565003 4 atıf (OpenAlex) Kaynak: OpenAlex

  26. Turkish Society of Medical Oncology COVID-19 Pandemic Advisory Board Updated Recommendations for Medical Oncologists: Included Vaccination

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2021-81962 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  27. Upfront thoracic radiotherapy to primary lession improve outcomes in patients with stage IV non-small cell lung cancer harboring EGFR mutations.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e21167 1 atıf (OpenAlex) Kaynak: OpenAlex

  28. Paraneoplastik Sendromların Nadir Örnekleri

    Turkiye Klinikleri Medical Oncology - Special Topics, 2021

    Kaynak: OpenAlex

  29. Impact of Baseline Neutrophil-to-Lymphocyte Ratio on Outcomes of GlioblastomaMultiforme Patients Treated with Standart Concurrent Chemoradiotherapy

    Acta Oncologica Turcica, 2021

    DOI 10.5505/aot.2021.81598 Açık erişimli tam metinKaynak: OpenAlex

  30. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

    European Urology Focus, 2020

    DOI 10.1016/j.euf.2020.09.010 PMID 33008789 8 atıf (Europe PMC) Kaynak: ORCID

  31. Concurrent versus sandwich treatment in adjuvant treatment in high risk operated gastric cancer: A single center experience

    Journal of B.U.ON., 2020

    PMID 33277854 Kaynak: ORCID

  32. Determination of the quality characteristics of naturally growing hawthorn in SuŞehri

    Acta Scientiarum Polonorum, Hortorum Cultus, 2020

    DOI 10.24326/asphc.2020.1.6 9 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  33. Identification of genetic diversity among Juglans regia L. genotypes using molecular, morphological, and fatty acid data

    Genetic Resources and Crop Evolution, 2020

    DOI 10.1007/s10722-020-01072-6 8 atıf (Europe PMC) Kaynak: ORCID

  34. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.6_suppl.451 3 atıf (OpenAlex) Kaynak: OpenAlex

  35. 781P Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.853 Açık erişimli tam metinKaynak: OpenAlex

  36. Turkish Medical Oncology Society COVID-19 Pandemic Advisory Board Recommendations for Cancer Patients and Medical Oncologist

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-75364 4 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  37. Adjuvant chemotherapy in gastric cancer

    Journal of Cancer Prevention & Current Research, 2020

    DOI 10.15406/jcpcr.2020.11.00431 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  38. Relationship Between Xanthine Oxidoreductase Activity and BRCA1 Levels in Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer Being Treated with Neoadjuvant Chemotherapy

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2019-71890 Açık erişimli tam metinKaynak: OpenAlex

  39. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study

    Archives of Medical Science, 2019

    DOI 10.5114/aoms.2019.83000 PMID 34336021 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  40. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

    Future oncology (London, England), 2019

    DOI 10.2217/fon-2018-0635 PMID 30977383 9 atıf (Europe PMC) Kaynak: ORCID

  41. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019

    DOI 10.1007/s00066-019-01429-6 PMID 30701292 8 atıf (Europe PMC) Kaynak: ORCID

  42. Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group

    Journal of B.U.ON., 2019

    Kaynak: ORCID

  43. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.7_suppl.308 2 atıf (OpenAlex) Kaynak: ORCID

  44. The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.7_suppl.316 1 atıf (OpenAlex) Kaynak: ORCID

  45. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

    Cancer Chemotherapy and Pharmacology, 2018

    DOI 10.1007/s00280-018-3712-7 PMID 30377778 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  46. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

    Annals of Oncology, 2018

    DOI 10.1093/annonc/mdy272.315 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  47. Prognostic value of basal neutrophil lymphocyte ratio in patients with extensive stage small cell lung cancer

    Çukurova medical journal (Online)/Çukurova medical journal, 2018

    DOI 10.17826/cumj.458042 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  48. Does cyclin E and p57kıp2 expression have prognostic and survival value in colorectal adenocarcinoma?

    International journal of clinical and experimental pathology, 2018

    PMID 31949774 Açık erişimli tam metinKaynak: ORCID

  49. Genetic polymorphisms in human telomerase reverse transcriptase (hTERT) gene polymorphisms do not associated with breast cancer in patients in a turkish population: hospital-based case-control study.

    Cellular and molecular biology (Noisy-le-Grand, France), 2018

    DOI 10.14715/cmb/2018.64.1.3 PMID 29506639 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  50. Clinicohistopathological features and treatment outcomes in testicular lymphomas: A single center experience

    Journal of Clinical Oncology, 2018

    DOI 10.1200/jco.2018.36.15_suppl.e16533 Kaynak: ORCID